Epidemiology

High burden of extended-spectrum β-lactamase-positive Escherichia coli in geriatric patients

  • 1Department of Microbiology and Carol Yu Centre for Infection, University of Hong Kong, Hong Kong Special Administrative Region, PR China
  • 2School of Nursing, University of Hong Kong, Hong Kong Special Administrative Region, PR China
  • Correspondence
    Pak-Leung Ho plho{at}hkucc.hku.hk
  • Journal of Medical Microbiology 2014; 63(Pt 6):878–883 · https://doi.org/10.1099/jmm.0.068270-0

    View at publisher PubMed

    With thanks to our partners for supporting this archive.

    Abstract

    Few studies have described how an expanding elderly population influences the burden of antimicrobial resistance in micro-organisms. This study aimed to investigate trends in age-stratified extended-spectrum β-lactamase (ESBL)-positive Escherichia coli metrics in relation to an ageing population. The antimicrobial resistance database of E. coli from a healthcare region in Hong Kong from 2003 to 2012 was retrospectively reviewed. Future trends in age-stratified ESBL metrics were predicted up to 2022. Susceptibility results of clinical E. coli isolates from patients aged 0–74 years (n = 17 853) and aged ≥75 years (n = 17 047) were analysed. For the period 2003–2012, 23.7 % of the hospital admissions were of patients aged ≥75 years. However, approximately half of the annual ESBL-positive E. coli isolates were recovered from patients aged ≥75 years, being 55.0 % (233/424) in 2003 and 56.0 % (639/1142) in 2012. During this period of time, the annual prevalence and cumulative incidence of ESBL-positive E. coli in patients aged ≥75 years were significantly higher than in patients aged 0–74 years. From 2012–2022, it is predicted that ESBL-positive E. coli prevalence among patients aged 0–74 years and ≥75 years would increase from 25.4 % to 50.2 % and from 30.8 % to 70.0 %, respectively. In 2022, the predicted ESBL-positive E. coli cumulative incidence would be 63.7 per 10 000 admissions and 178.7 per 10 000 admissions among patients aged 0–74 years and ≥75 years, respectively. In conclusion, a rapidly expanding elderly population would substantially add to the burden of ESBL.

    • These authors contributed equally to this paper.

    Abbreviations:
    ESBL
    extended-spectrum β-lactamase